# IFM 2022-01: HCP commentary report

> 15 verified statements (7 from clinicians verified by NPI or staff page) from 4 commentary sources · 5 findings · updated Oct 28, 2026

## Report

- Trial: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)
- NCT ID: NCT06353022
- Registry: https://clinicaltrials.gov/study/NCT06353022
- Sponsor: Nantes University Hospital
- Phase: Phase 2
- Status: Active, not recruiting
- Drugs: teclistamab, talquetamab, lenalidomide, bortezomib, daratumumab, dexamethasone
- Indications: Multiple myeloma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-28
- Last checked: 2026-10-28
- Release hash: a7ac1b5d4e0056a8c2c694020a86232e35ca63b6e9e151df443d8a60768582d9

## Counts

- HCP commentary sources screened: 8
- Sources cited by verified statements: 4
- Verified statements: 15
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 7
- Findings: 5
- People found in screened sources: 3
- People identity-verified: 3
- Voices cited: 3

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

IFM 2022-01 examines whether using residual disease testing to guide T-cell redirectors after induction can deepen responses in newly diagnosed multiple myeloma. Clinicians in the sources reviewed for this edition question the place of autologous stem-cell transplantation, while the route to upfront T-cell redirection remains unsettled. Early MRD conversion draws enthusiasm, while its distinction from sustained negativity draws scrutiny. How these responses should inform transplantation and the timing of T-cell redirection remains open.

## Open Medical Affairs question

What evidence would justify shorter exposure or different sequencing while preserving durable benefit and limiting harm?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Enthusiasm for early MRD conversion is qualified by the distinction between undetectable and sustained MRD
- F2. Rapid responses prompt a question about two years of exposure, alongside concern about cumulative toxicity
- F3. ASCT is questioned, while the route to upfront T-cell redirection remains unsettled
- F4. High-risk and ultra-high-risk patients qualify the optimistic frontline outlook
- F5. Avoiding neuropathy is part of one speaker's longer-term vision for frontline treatment

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 4 | 5 | 4 | 3 | none recorded | 2 |
| F2 | 4 | 3 | 3 | 2 | none recorded | 2 |
| F3 | 4 | 2 | 2 | 1 | none recorded | 2 |
| F4 | 2 | 1 | 1 | 0 | none recorded | 2 |
| F5 | 2 | 1 | 1 | 0 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 3 | 0 | 0 | 0 | 1 | 4 | 1 | 3 posts and articles, 1 podcast or video | yes |
| F2 | 3 | 1 | 0 | 0 | 0 | 4 | 0 | 2 posts and articles, 1 podcast or video | yes |
| F3 | 2 | 1 | 0 | 0 | 1 | 5 | 0 | 1 post or article, 1 podcast or video | yes |
| F4 | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 1 podcast or video | yes |
| F5 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Rate of sustained MRD negativity (NGS, 10^-5): F1 (1 shared claims)
- Primary endpoint: Rate of conversion from positive MRD to negative MRD (NGS, 10^-5): F1 (4 shared claims), F3 (1 shared claims)
- Secondary endpoints: F1 (1 shared claims), F2 (1 shared claims)
- Population and setting: F1 (3 shared claims), F3 (1 shared claims)
- The comparison: no finding draws on it directly
- Safety and tolerability: F2 (1 shared claims)
- Design and conduct: no finding draws on it directly

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. Enthusiasm for early MRD conversion is qualified by the distinction between undetectable and sustained MRD

The methodological question addressed in X-thread commentary is how to distinguish early MRD clearance from sustained negativity.

Source: X thread, 2026-09-25.

### F3. ASCT is questioned, while the route to upfront T-cell redirection remains unsettled

The evidence-assessment question arising from X-thread commentary is what evidence would be needed to evaluate changes in transplantation practice.

Source: X thread, 2026-09-25.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 15 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 4 | Counts free |
| Speaker attribution for cited voices | 3 | Paid |

## Trial aspects

9 discussed · 2 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Rate of sustained MRD negativity (NGS, 10^-5) | discussed | 1 | 1 |
| Primary endpoint: Rate of conversion from positive MRD to negative MRD (NGS, 10^-5) | discussed | 4 | 4 |
| Secondary endpoints | discussed | 2 | 1 |
| Population and setting | discussed | 3 | 3 |
| The comparison | no commentary found | 0 | 0 |
| Safety and tolerability | discussed | 1 | 1 |
| Design and conduct | no commentary found | 0 | 0 |
| Treatment duration and stopping | discussed | 4 | 3 |
| ASCT and the route to upfront T-cell redirection | discussed | 4 | 2 |
| High-risk and ultra-high-risk unmet need | discussed | 2 | 1 |
| Future bortezomib removal and patient experience | discussed | 2 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 6 | 3 |
| YouTube | 1 | 1 |
| Bluesky threads | 1 | 0 |

- Screened window: 2026-09-25 to 2026-10-23
- Cited window: 2026-09-25 to 2026-09-26
- Retrieved: 2026-10-28

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)
- Registry: NCT06353022 (https://clinicaltrials.gov/study/NCT06353022)
- Study IDs: RC23_0267 · 2023-508310-41
- Sponsor: Nantes University Hospital
- Collaborators: Janssen Pharmaceutica
- Design: Phase 2 · interventional, non randomized, parallel, phase2
- Status: Active, not recruiting
- Enrollment: 103 (estimated)
- Start: 2024-06-26 (actual)
- Primary completion: 2028-04-26 (estimated)
- Primary endpoint: Rate of sustained MRD negativity (NGS, 10^-5) (38 months)
- Primary endpoint: Rate of conversion from positive MRD to negative MRD (NGS, 10^-5) (38 months)
- Intervention: Teclistamab (drug)
- Intervention: Talquetamab (drug)
- Intervention: Lenalidomide (drug)
- Intervention: Bortezomib (drug)
- Intervention: Daratumumab (drug)
- Intervention: Dexamethasone (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 3 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- These views are not a representative survey of HCP opinion. Reposts do not establish additional independent clinician views or endorsement.
- Discussion that omits the trial name or uses different wording may be missing. Some portions of the X and video discussions were not fully assessed, so additional or differing views may be absent.
- The video speaker cannot be identified from the spoken material reviewed; the publisher's description does not resolve that uncertainty.
- No publication for NCT06353022 was found for this edition, and the registry did not list a protocol. The comments cannot substitute for a full assessment of study methods or outcomes.
- The regulatory material reviewed was incomplete and did not include an exact talquetamab label. The safety discussion is not a comprehensive risk assessment.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-28: current edition, corrected 2026-10-28
  - Correction 2026-10-28: The trial is named IFM 2022-01, as its sources and the report name it (was IFm2022-01)

Last checked for new commentary 2026-10-28. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (15 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (3 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/ifm2022-01-nct06353022
- Agents: POST https://www.erudio.com/api/orders with {"report": "ifm2022-01-nct06353022", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=ifm2022-01-06353022

## Cite

Erudio Health. IFM 2022-01 (NCT06353022): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 28, 2026. https://www.erudio.com/reports/ifm2022-01-nct06353022

## Machine access

- JSON: https://www.erudio.com/reports/ifm2022-01-nct06353022.json
- Markdown: https://www.erudio.com/reports/ifm2022-01-nct06353022.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "ifm2022-01-06353022"}`